BIOMERICA INCBMRAEarnings & Financial Report
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
Revenue
$1.6M
Gross Profit
$325.0K
Operating Profit
$-1.6M
Net Profit
$-1.5M
Gross Margin
20.7%
Operating Margin
-102.6%
Net Margin
-96.2%
YoY Growth
5.7%
EPS
$-0.09
BIOMERICA INC Q2 FY2024 Financial Summary
BIOMERICA INC reported revenue of $1.6M (up 5.7% YoY) for Q2 FY2024, with a net profit of $-1.5M (up 7.3% YoY) (-96.2% margin). Cost of goods sold was $1.2M, operating expenses totaled $1.9M.
Key Financial Metrics
| Total Revenue | $1.6M |
|---|---|
| Net Profit | $-1.5M |
| Gross Margin | 20.7% |
| Operating Margin | -102.6% |
| Report Period | Q2 FY2024 |
BIOMERICA INC Annual Revenue by Year
BIOMERICA INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $5.4M).
| Year | Annual Revenue |
|---|---|
| 2024 | $5.4M |
| 2023 | $5.3M |
| 2022 | $18.9M |
BIOMERICA INC Quarterly Revenue & Net Profit History
BIOMERICA INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $1.2M | -26.0% | $-1.3M | -109.1% |
| Q1 FY2026 | $1.4M | -23.6% | $2.0K | 0.1% |
| Q3 FY2025 | $1.1M | +10.0% | $-1.2M | -103.9% |
| Q2 FY2025 | $1.6M | +4.4% | $-950.0K | -58.1% |
| Q1 FY2025 | $1.8M | +5.5% | $-1.3M | -72.8% |
| Q4 FY2024 | $1.1M | +0.8% | $-1.4M | -127.1% |
| Q3 FY2024 | $1.0M | -8.5% | $-1.9M | -188.6% |
| Q2 FY2024 | $1.6M | +5.7% | $-1.5M | -96.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $1.1M | $1.8M | $1.6M | $1.1M | $1.4M | $1.2M |
| YoY Growth | 5.7% | -8.5% | 0.8% | 5.5% | 4.4% | 10.0% | -23.6% | -26.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.8M | $10.3M | $9.3M | $7.9M | $7.3M | $7.4M | $6.9M | $6.0M |
| Liabilities | $2.4M | $2.5M | $2.7M | $2.5M | $2.2M | $1.8M | $1.7M | $1.6M |
| Equity | $9.4M | $7.8M | $6.6M | $5.3M | $5.1M | $5.5M | $5.2M | $4.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-842000 | $-1.8M | $-1.0M | $-1.3M | $-791000 | $-1.0M | $-268000 | $-991000 |